Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study
Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study
BACKGROUND: Bacterial infections are associated with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but the mechanism is incompletely understood.
METHOD: In a COPD observational study (NCT01360398), sputum samples were collected monthly at the stable state and exacerbation. Post-hoc analyses of 1307 non-typeable Haemophilus influenzae (NTHi) isolates from 20 patients and 756 Moraxella catarrhalis isolates from 38 patients in one year of follow-up were conducted by multilocus sequence typing (MLST). All isolates came from cultured sputum samples that were analyzed for bacterial species presence, apparition (infection not detected at the preceding visit), or acquisition (first-time infection), with the first study visit as a baseline. Strain apparition or new strain acquisition was analyzed by MLST. The odds ratio (OR) of experiencing an exacerbation vs. stable state was estimated by conditional logistic regression modelling, stratified by patient.
RESULTS: The culture results confirmed a significant association with exacerbation only for NTHi species presence (OR 2.28; 95% confidence interval [CI]: 1.12-4.64) and strain apparition (OR 2.38; 95% CI: 1.08-5.27). For M. catarrhalis, although confidence intervals overlapped, the association with exacerbation for first-time species acquisition (OR 5.99; 2.75-13.02) appeared stronger than species presence (OR 3.67; 2.10-6.40), new strain acquisition (OR 2.94; 1.43-6.04), species apparition (OR 4.18; 2.29-7.63), and strain apparition (OR 2.78; 1.42-5.42). This may suggest that previous M. catarrhalis colonization may modify the risk of exacerbation associated with M. catarrhalis infection.
CONCLUSIONS: The results confirm that NTHi and M. catarrhalis infections are associated with AECOPD but suggest different dynamic mechanisms in triggering exacerbations.
Exacerbation, Moraxella catarrhalis, acquisition, apparition, bacteria, non-typeable Haemophilus influenzae
784-793
Malvisi, Lucio
6768f9f8-5f6e-450c-b7b5-6936c0ea02c7
Yarraguntla, Aparna
c4345883-3707-452b-9fe5-4f99cf3e007b
Mortier, Marie-Cecile
85ae928d-84fb-46c5-ac19-15e85f4fac51
Osman, Karen L
9df79583-5da6-480e-ad25-189e8a4d63f2
Cleary, David
f4079c6d-d54b-4108-b346-b0069035bec0
Sente, Beatrice
1353e078-ef78-473d-be5b-1f3b7b3ebcf1
Pascal, Thierry G.
d29c2776-30a8-4ac4-b467-f3606c7e9f59
Weynants, Vincent
36b1f098-a1fb-444f-acb1-d85009cc6d4c
Clarke, Stuart
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
Taddei, Laura
ee434698-2918-4af4-afbb-9de9ff893653
Wilkinson, Tom M.A.
1583ef8c-8ca9-4d46-ae60-0b3556090d8f
Devaster, Jeanne-Marie
36195bcf-0cae-40cc-8ee2-d389a4a65a13
Devos, Nathalie
376b1648-5ac2-4c5e-92c7-9cf228fda87c
Wootton, Stephen
bf47ef35-0b33-4edb-a2b0-ceda5c475c0c
2 November 2022
Malvisi, Lucio
6768f9f8-5f6e-450c-b7b5-6936c0ea02c7
Yarraguntla, Aparna
c4345883-3707-452b-9fe5-4f99cf3e007b
Mortier, Marie-Cecile
85ae928d-84fb-46c5-ac19-15e85f4fac51
Osman, Karen L
9df79583-5da6-480e-ad25-189e8a4d63f2
Cleary, David
f4079c6d-d54b-4108-b346-b0069035bec0
Sente, Beatrice
1353e078-ef78-473d-be5b-1f3b7b3ebcf1
Pascal, Thierry G.
d29c2776-30a8-4ac4-b467-f3606c7e9f59
Weynants, Vincent
36b1f098-a1fb-444f-acb1-d85009cc6d4c
Clarke, Stuart
f7d7f7a2-4b1f-4b36-883a-0f967e73fb17
Taddei, Laura
ee434698-2918-4af4-afbb-9de9ff893653
Wilkinson, Tom M.A.
1583ef8c-8ca9-4d46-ae60-0b3556090d8f
Devaster, Jeanne-Marie
36195bcf-0cae-40cc-8ee2-d389a4a65a13
Devos, Nathalie
376b1648-5ac2-4c5e-92c7-9cf228fda87c
Wootton, Stephen
bf47ef35-0b33-4edb-a2b0-ceda5c475c0c
Malvisi, Lucio, Yarraguntla, Aparna, Mortier, Marie-Cecile, Osman, Karen L, Cleary, David, Sente, Beatrice, Pascal, Thierry G., Weynants, Vincent, Clarke, Stuart, Taddei, Laura, Wilkinson, Tom M.A., Devaster, Jeanne-Marie, Devos, Nathalie and Wootton, Stephen
(2022)
Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study.
Infectious Diseases, 54 (11), .
(doi:10.1080/23744235.2022.2092648).
Abstract
BACKGROUND: Bacterial infections are associated with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but the mechanism is incompletely understood.
METHOD: In a COPD observational study (NCT01360398), sputum samples were collected monthly at the stable state and exacerbation. Post-hoc analyses of 1307 non-typeable Haemophilus influenzae (NTHi) isolates from 20 patients and 756 Moraxella catarrhalis isolates from 38 patients in one year of follow-up were conducted by multilocus sequence typing (MLST). All isolates came from cultured sputum samples that were analyzed for bacterial species presence, apparition (infection not detected at the preceding visit), or acquisition (first-time infection), with the first study visit as a baseline. Strain apparition or new strain acquisition was analyzed by MLST. The odds ratio (OR) of experiencing an exacerbation vs. stable state was estimated by conditional logistic regression modelling, stratified by patient.
RESULTS: The culture results confirmed a significant association with exacerbation only for NTHi species presence (OR 2.28; 95% confidence interval [CI]: 1.12-4.64) and strain apparition (OR 2.38; 95% CI: 1.08-5.27). For M. catarrhalis, although confidence intervals overlapped, the association with exacerbation for first-time species acquisition (OR 5.99; 2.75-13.02) appeared stronger than species presence (OR 3.67; 2.10-6.40), new strain acquisition (OR 2.94; 1.43-6.04), species apparition (OR 4.18; 2.29-7.63), and strain apparition (OR 2.78; 1.42-5.42). This may suggest that previous M. catarrhalis colonization may modify the risk of exacerbation associated with M. catarrhalis infection.
CONCLUSIONS: The results confirm that NTHi and M. catarrhalis infections are associated with AECOPD but suggest different dynamic mechanisms in triggering exacerbations.
Text
23744235.2022.2092648
- Accepted Manuscript
More information
e-pub ahead of print date: 6 July 2022
Published date: 2 November 2022
Additional Information:
Funding Information:
LM, MCM, BS, TGP, VW, LT, JMD, and ND are employed by GSK, and LT, TGP, VW, JMD, and ND hold shares in GSK. VW and JMD are designated inventors on patents owned by GSK. AY was a consultant of ICON for GSK during the conduct of the study and is now employed by GSK. KO received a grant from GSK during the conduct of her Ph.D. DWC reports a grant from GSK during the conduct of this study. SCC received a grant from Pfizer outside of the submitted work and a grant from GSK during the conduct of the study. TMAW has received grants and non-financial support from GSK during the conduct of the study as well as grants from AstraZeneca, Synairgen, and MyMHealth and fees, reimbursement for travel, and meeting attendance from Boehringer Ingelheim, Chiesi, AstraZeneca, Synairgen, and MyMHealth outside of the submitted work. In addition, TMAW has a patent 2018 US Patent 62/479562—Immunogenic Composition, Use and Methods of Treatment—A novel vaccine to prevent exacerbations of COPD pending to GSK and is Founder and Director of MyMHealth Ltd. All authors declare having no other financial and non-financial relationships and activities.
Publisher Copyright:
© 2022 GlaxoSmithKline Biologicals S.A. Published by Informa UK Limited, trading as Taylor & Francis Group.
Keywords:
Exacerbation, Moraxella catarrhalis, acquisition, apparition, bacteria, non-typeable Haemophilus influenzae
Identifiers
Local EPrints ID: 467965
URI: http://eprints.soton.ac.uk/id/eprint/467965
PURE UUID: 72a740be-6a90-4476-830e-ba4b546caf9f
Catalogue record
Date deposited: 26 Jul 2022 17:10
Last modified: 06 Jun 2024 04:02
Export record
Altmetrics
Contributors
Author:
Lucio Malvisi
Author:
Aparna Yarraguntla
Author:
Marie-Cecile Mortier
Author:
Karen L Osman
Author:
Beatrice Sente
Author:
Thierry G. Pascal
Author:
Vincent Weynants
Author:
Laura Taddei
Author:
Tom M.A. Wilkinson
Author:
Jeanne-Marie Devaster
Author:
Nathalie Devos
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
